Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
DREAMM-2 clinical trial
BLENREP efficacy
Learn how fast, deep and durable responses to BLENREP were in a triple-class refractory multiple myeloma (MM) patient population1-3
For GB healthcare professionals only.*
Table of contents
The DREAMM-2 clinical trial studied BLENREP as a single agent in triple-class refractory patients with multiple myeloma (MM) (n=97; 13-month follow-up) who had received a median of 7 prior lines of therapy.1
BLENREP is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.2,3
-
DREAMM-2 clinical trial design
- DREAMM-2 was an open-label, multicentre, phase 2 study in patients with relapsed/refractory multiple myeloma2
- Patients were refractory to an anti-CD38 antibody, a proteasome inhibitor, and an immunomodulatory agent2
HSCT, haematopoietic stem cell transplantation.
-
DREAMM-2 patient characteristics
Baseline characteristics in the recommended dose population2
Adapted from Lonial S, et al. Lancet Oncol. 2020. Data are n (%) unless otherwise specified.
eGFR, estimated glomerular filtration rate; IgG, immunoglobulin G; ISS, International Staging System.
*Data available for 47 patients in the 2.5 mg/kg cohort and 36 patients in the 3.4 mg/kg cohort.2
†The number of previous lines of therapy is derived as the number of previous anticancer regimens received by a patient as reported on the electronic case report form. Combination therapy containing multiple components was counted as one regimen.2
‡Based on data available at the time of database lock; however, all patients were refractory to a proteasome inhibitor, immunomodulatory drug,and an anti-CD38 monoclonal antibody as per eligibility criteria.2
Watch Dr Rakesh Popat present the DREAMM-2 clinical trial, including DREAMM-2 efficacy results, safety data, and how eye-related side effects were managed.
DREAMM-2 results at 13 month follow up
Secondary endpoint: OS1
Results at 13-month follow up: median OS was 13.7 months (95% CI: 9.9-NR).1
Adapted from Lonial S, et al. Cancer. 2021.
CI, confidence interval; NR, not reached; OS, overall survival.
OS by response category1
Median OS not reached for responding patients at 13-month follow-up.1
Adapted from Lonial S, et al. Cancer. 2021.
MR, minimal response; NE, not evaluable; PD, progressive disease; PR, patrial response; SD, stable disease.
DREAMM-2 results at 13 month follow up
Duration of response (DoR)1
The median duration of response was 11.0 months (95% CI; 4.2-NR)
Adapted from Lonial S, et al. Cancer. 2021.
CI, confidence interval; DoR, duration of response; MR, minimal response; NR, not reached; PR, partial response.
DREAMM-2 results at 13 month follow up
The estimated duration of clinical benefit (MR or better) was 11.7 months (95% CI: 4.2-NR)1
Adapted from Lonial S, et al. Cancer. 2021.
CI, confidence interval; MR, minimal response; NR, not reached.
DREAMM-2 results at 13 month follow up
Progression-free survival (PFS)1
Median PFS was 2.8 months (95% CI: 1.6-3.6).1
Adapted from Lonial S, et al. Cancer. 2021.
CI, confidence interval; PFS, progression-free survival.
DREAMM-2 results at 13 month follow up
PFS by response category1
BLENREP delivered greater than 12 months progression-free survival in patients with a minimal response or better.1
Adapted from Lonial S, et al. Cancer. 2021.
MR, minimal response; NE, not estimable; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease.
BLENREP delivered similar responses in patient sub-groups vs. the overall population1
Analysis at 13 month follow up
*Analysis included patients with t(4;14), t(14;16), or 17p13del translocations. Evaluation of BLENREP in patients with these high-risk cytogenetics was a prespecified subgroup analysis and not adjusted for multiplicity. In a post-hoc analysis that also included patients with the 1q21+ abnormality, the ORR was 29% (n=12/41; 95% CI: 16.1–45.5).1
ORR based on renal function (post-hoc analysis)1
| Renal function | ORR |
|---|---|
| Normal renal function (≥90 mL/min/1.73 m2; n=19) |
37% (95% CI: 16.3-61.6) |
| Mild renal impairment (≥60–<90 mL/min/1.73 m2; n=48) |
33% (95% CI: 20.4-48.4) |
| Moderate renal impairment (≥30–<60 mL/min/1.73 m2; n=24) |
33% (95% CI: 15.6-55.3) |
Find out more about what BLENREP can offer your patients
*BLENREP is not commercially available in Northern Ireland.
BLENREP is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.3
Abbreviations
CI, confidence interval; DoR, duration of response; DREAMM-2, DRiving Excellence in Approaches to Multiple Myeloma 2; eGFR, estimated glomerular filtration rate; HSCT, haematopoietic stem cell transplantation; IgG, immunoglobulin G; ISS, International Staging System; MM, multiple myeloma; MR, minimal response; NE, not evaluable; NR, not reached; OS, overall survival; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease; TTBR, time to best response; TTR, time to response; VGPR, very good partial response.
References
- Lonial S, et al. Cancer. 2021;127(22):4198–4212.
- Lonial S, et al. Lancet Oncol. 2020;21(2):207–221.
- BLENREP Summary of Product Characteristics.
- Palumbo A, et al. Blood. 2011;118(17):4519–4529.
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441
© 2022 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.
October 2022 | PM-GB-BLM-WCNT-220003 (V1.0)
